Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06830798 · ClinicalTrials.gov registry record · Phase 3

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

A Phase 3 study of Kidney Transplant and Delayed Graft Function, sponsored by Alexion Pharmaceuticals.

Recruiting
Registry status
Phase 3
Development phase
450
Enrollment target
20
Study locations

NCT06830798 is a Phase 3 study of Kidney Transplant and Delayed Graft Function that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 450 participants, below the 1,883-participant average among 30 other Kidney Transplant trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06830798, a Phase 3 study of Kidney Transplant and Delayed Graft Function, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.

RECRUITING
Registry status
Phase 3
Development phase
450 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

Conditions Studied

Kidney Transplant Delayed Graft Function DGF

Interventions

  • DRUG Placebo
  • DRUG Ravulizumab

Study Locations (20)

California

  • Research Site - Los Angeles
  • Research Site - San Francisco
  • Research Site - San Francisco
  • Research Site - Stanford

Florida

  • Research Site - Jacksonville
  • Research Site - Tampa

Illinois

  • Research Site - Chicago
  • Research Site - Chicago

Michigan

  • Research Site - Ann Arbor
  • Research Site - Detroit

Arizona

  • Research Site - Phoenix

Connecticut

  • Research Site - New Haven

Georgia

  • Research Site - Atlanta

Kansas

  • Research Site - Fairway

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2025-05-19
Est. Completion 2028-11-06
Phase Phase 3

Sponsor

Alexion Pharmaceuticals

162 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06830798

The ClinicalTrials.gov registry entry for NCT06830798 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,883-participant average among 30 other Kidney Transplant trials with a reported enrollment target (76% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Kidney Transplant appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06830798 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT06830798 about?

NCT06830798 is a clinical study titled "Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation". The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

What is the current status of trial NCT06830798?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2025-05-19. Estimated completion is 2028-11-06.

What conditions does trial NCT06830798 study?

This clinical trial studies the following conditions: Kidney Transplant, Delayed Graft Function, DGF.

What interventions are being tested in trial NCT06830798?

The interventions under investigation include: Placebo (DRUG), Ravulizumab (DRUG).

Who is sponsoring clinical trial NCT06830798?

This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06830798 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Kidney Transplant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Kidney Transplant

All registered trials for this condition

Delayed Graft Function

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.